0001225208-24-001597.txt : 20240205
0001225208-24-001597.hdr.sgml : 20240205
20240205183744
ACCESSION NUMBER: 0001225208-24-001597
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240205
FILED AS OF DATE: 20240205
DATE AS OF CHANGE: 20240205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MUSSALLEM MICHAEL A
CENTRAL INDEX KEY: 0001204551
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15525
FILM NUMBER: 24597398
MAIL ADDRESS:
STREET 1: C/O EDWARDS LIFESCIENCES CORP
STREET 2: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edwards Lifesciences Corp
CENTRAL INDEX KEY: 0001099800
STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 364316614
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
BUSINESS PHONE: 9492502500
MAIL ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP.
DATE OF NAME CHANGE: 20090225
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP
DATE OF NAME CHANGE: 20000203
FORMER COMPANY:
FORMER CONFORMED NAME: CVG CONTROLLED INC
DATE OF NAME CHANGE: 19991126
4
1
doc4.xml
X0508
4
2024-02-05
0001099800
Edwards Lifesciences Corp
EW
0001204551
MUSSALLEM MICHAEL A
ONE EDWARDS WAY
IRVINE
CA
92614
1
1
Common Stock
2024-02-05
4
M
0
29350.0000
36.7500
A
33835.8200
D
Common Stock
2024-02-05
4
S
0
1000.0000
89.6100
D
32835.8200
D
Common Stock
2024-02-05
4
S
0
6422.0000
88.6300
D
26413.8200
D
Common Stock
2024-02-05
4
S
0
9761.0000
86.4400
D
16652.8200
D
Common Stock
2024-02-05
4
S
0
12167.0000
87.5500
D
4485.8200
D
Common Stock
4038377.0000
I
By Living Trust
Employee Stock Option (Right to Acquire)
36.7500
2024-02-05
4
M
0
29350.0000
0.0000
D
2017-06-11
2024-05-10
Common Stock
29350.0000
88050.0000
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.
This transaction was executed in multiple trades at prices ranging from $89.390 to $90.080. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $88.210 to $89.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $86.100 to $87.070. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $87.110 to $88.105. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact
2024-02-05